Date: April 14 2021 (Wednesday)
Time: 8 - 10 PM (GMT+8)

<<Lecture Information>>
Cancer immunotherapy, ‘the breakthrough of the year 2013’- as heralded by the journal Science, represents one of the most promising modern-age modalities for the treatment of cancers. Immunotherapies aim to re-educate the immune system to recognize, attack and eliminate cancer cells. Immunotherapy-induced anti-cancer immune responses not only eliminate existing cancer cells, but also maintain an active surveillance against future cancer relapse. Indeed, these anti-cancer immunotherapies are believed to be the key in achieving long-term cancer-free human health.

Dr. Shashi Gujar’s research portfolio aims to develop novel interventions that simultaneously target cancer cells, thwart immune checkpoints and promote the long-term anti-tumor immunity. His laboratory has brought together complimentary expertise in the fields of MHC ligandome discovery, oncolytic virus-induced immunotherapies, autophagic as well as immunogenic cell death to achieve these goals, and is focused on the discovery of novel cancer immunotherapeutic modalities including using oncolytic viruses that specifically target cancer cells. Dr. Gujar’s research endeavor is based on the strong belief that these cutting-edge cancer immunology research and development efforts bear great potential, and most importantly, promise to produce the next-generation of cancer immunotherapy options that can be easily translated into clinical settings.

<<Speaker Introduction>>
Dr. Shashi Gujar is an assistant professor and research scientist in the Department of Pathology and the Department of Microbiology & Immunology at Dalhousie University. He is also the Head of the Laboratory for Cancer Metabolism, Cell Biology & Immunotherapies. Dr. Gujar’s research program focuses on molecular and immunological aspects of human health, with special focus on cancer immunotherapies. His multi-disciplinary interests include Oncolytic viruses, Immunology and immunotherapies, Epitope discovery, Cellular biology and metabolism, Applied immunomics and Proteo-immuno-metabolomics. Dr. Gujar’s laboratory has developed cutting-edge technology platforms that leverage the latest developments in the areas of immunology, metabolism, and multiOMICs. Using these innovative approaches, his team intends to discover the next generation of cancer immunotherapies which will aid the prevention, diagnosis, and treatment of cancers.

* This lecture will be held via Google Meet. The link will be provided after you complete the online registration.

* 2 points for TMU Global Learning Passport for students. 2 hours of TMU education training credits for faculty.

* For more information, please contact International Research Section (ogeirs@tmu.edu.tw)
==========================================================================

活動日期/時間：2021年4月14日 (三)/ 晚上8 - 10點 (GMT+8)

講座資訊
癌症免疫療法是 "2013年的突破"--正如《科學》雜誌所預示的那樣，它代表了現代醫學最具發展前途的癌症治療方式之一。免疫療法旨在重新教育免疫系統識別、攻擊和消除癌細胞。免疫療法誘導的抗癌免疫反應不僅能消滅現有的癌細胞，而且還能維持對未來癌症復發的主動監控；事實上，這些抗癌免疫療法被認為是可能實現人類長期無癌健康的關鍵。

Shashi Gujar博士的研究致力於開發可同時削弱癌細胞、抑制免疫檢查點和促進長期抗腫瘤免疫的新型治療方式。為了實現這個目標，他的團隊整合了MHC配體組、溶瘤病毒免疫療法、細胞自噬以及免疫誘發細胞死亡等多領域的專業技術，並專注於開發新型的癌症免疫治療方式，包括使用專門針對癌細胞的溶瘤病毒。這些尖端的癌症免疫學研究和開發工作具有巨大的潛力，最重要的是此研究成果能使新一代癌症免疫療法有更多選項，並能被轉譯於臨床使用。

講者介紹
Shashi Gujar博士是加拿大達爾豪斯大學病理學系、微生物學和免疫學系的助理教授和研究科學家，也是癌症代謝、細胞生物學和免疫療法實驗室的負責人。Gujar博士的研究著重於人類健康的分子及免疫學層面，特別是癌症免疫療法。他的多領域研究興趣包括：溶瘤病毒、免疫學和免疫療法、抗原決定位發現、細胞生物學和代謝、應用免疫體學和蛋白免疫代謝體學。Gujar博士的實驗室利用免疫學、代謝學和多組學(Multi-omics) 等領域的最新發展開發了許多尖端技術平台。利用這些新穎的研究方法，他的團隊致力於開發新一代癌症免疫療法，這將有助於癌症的預防、診斷和治療。

* 此次講座將透過Google Meet 進行。線上會議連結將於完成下方活動報名時提供。

* 學生可認列北醫國際學習護照2點。教職員可認列訓練時數2小時。

* 如有任何問題，請聯繫國際研究組 (ogeirs@tmu.edu.tw)